Pavilion Publishing and Media Ltd
Blue Sky Offices Shoreham, 25 Cecil Pashley Way, Shoreham-by-Sea, West Sussex, BN43 5FF, UNITED KINGDOM
Tel: +44 (0)1273 434 943
Email: [email protected]
A new fixed-combination foam spray for the treatment of plaque psoriasis has been launched by Leo Pharma. The cutaneous foam spray is the first of its type to be available in the UK.
Data shows that Enstilar (calcipotriol/betamethasonedipropionate 50 micrograms/g + 0.5 mg/g) is a more effective topical combination treatment than those currently available, is generally well-tolerated, with more than half of patients in clinical trials experiencing significant visible signs of improvement within four weeks and with some patients seeing improvements at one week.
The treatment also shows positive performance in improving patients’ quality of life (QoL). In total, 75% of patients believe their quality of life is significantly impacted by psoriasis, both emotionally and physically, yet 81% of psoriasis patients using Enstilar foam spray in trials reported QoL improvements after four weeks, with more than 70% seeing a reduction in itch-related sleep loss. The symptomatic relief experienced by the majority of patients may be attributed to the cooling effect of the new foam spray.
Professor Chris Griffiths, Foundation Professor of Dermatology at The University of Manchester, said: “Enstilar foam spray represents a welcome new choice of topical therapy for people with plaque psoriasis, particularly those who wish to explore new options with their GP and/or whose next step would be a referral to consider transitioning to systemic therapy.
“Clinical data point to the superior efficacy of Enstilar over other topical combination therapies and to a favourable safety profile.”
John Warne, Founder, Psoriasis Help Organisation, said: “We are delighted that there is a new, effective treatment choice now available to treat plaque psoriasis, an area of significant unmet need.
“Over 1.5 million people across the UK are living each day with the significant challenges of this chronic skin condition so we welcome new options to help them take back control.”
Adherence is a significant challenge for patients living with psoriasis: studies consistently suggest that up to 40% of people with psoriasis do not use their medication as directed. In recognition of this challenge and to help patients achieve optimal outcomes, LEO Pharma has also developed a new suite of resources:
- Quality Care website – For more information about psoriasis visit: www.qualitycarebyleo.co.uk
- My Pso app – For practical advice to make small changes that can have a big impact on psoriasis, download the My Pso app at the Apple App Store or Google Play
- Nurse support line – To speak in confidence to a nurse before, during and after treatment call the dedicated nurse support line on 0800 090 2165 for the UK. Lines are open Monday to Friday from 08:30-17:00.